

VASCULAR ANOMALIES: A CHALLENGING DIFFERENTIAL DIAGNOSIS

ANOMALII VASCULARE: UN DIAGNOSTIC DIFERENȚIAL PROVOCATOR

MĂDĂLINA BOTA*, ALEXANDRU TĂTARU**

Rezumat

Anomaliile vasculare sunt tulburări complexe, frecvente care apar la sugari și copii. Clasificarea lor în două grupe majore, tumori și malformații, ajută la înțelegerea principalelor caracteristici ale ambelor tipuri. Cu toate acestea, ambele grupuri conțin mai multe alte tipuri care trebuie, de asemenea să fie diferențiate, iar acest lucru poate fi realizat clinic, imagistic sau prin abordare histopatologică. Tumorile sunt bazate pe proliferarea celulară, în timp ce malformațiile sunt reprezentate de modificări ale vaselor de sânge. În scopul de a diferenția, RMN și MRA sunt resursele de imagistică cele mai utilizate, dar biopsia este forma cea mai precisă pentru diagnostic și se realizează atunci când sunt dubii. În ceea ce privește tratamentul, tumorile sunt în mare parte tratate medical și malformațiile beneficiază de scleroterapie în majoritatea cazurilor. Laserterapia, radioterapia și chirurgia sunt opțiunile luate în considerare în câteva situații specifice.

Acest articol are ca scop să sublinieze cele mai importante caracteristici clinice ale fiecărei anomalii, cele mai utilizate diagnostice imagistice, și nu în ultimul rând, prezintă pe scurt abordarea cardinală de tratament a ambelor grupuri.

Cuvinte cheie: Anomalii vasculare, diagnostic diferențial.

Summary

Vascular anomalies are frequent complex disorders that appear in infants and children. Their classification in two major groups, tumors and malformations, helps understanding the main characteristics of both types. However, both groups contain several other types that need as well to be differentiated, and this can be done by clinical, imaging or histopathological approach. Tumors are based on cellular proliferation, while malformations are represented by aberrant vessels. In order to differentiate MRI and MRA are the most used imaging resources, but the biopsy is the most accurate form of diagnosis and is realized when in doubt. Regarding the treatment, tumors are mostly medically treated and malformations benefit of sclerotherapy in the majority of cases. Lasertherapy, radiotherapy and surgery are options taken into account in a few specific situations.

This review has the aim to underline the most important clinical characteristics of each anomaly, the most used imaging diagnosis and, last but not least, it briefly presents the cardinal treatment approach of both groups.

Key words: Vascular anomalies, differential diagnosis.

Intrat în redacție: 31.01.2014

Acceptat: 3.03.2014

Received: 31.01.2014

Accepted: 3.03.2014

* U.M.F. "I. Hațieganu", Cluj-Napoca, Dept. Pediatrics.

** U.M.F. "I. Hațieganu", Cluj-Napoca, Dept. Dermatology.

Introduction

Vascular anomalies are frequently seen in infants and children, and are of utmost importance to differentiate. Based on their pathological characteristics vascular anomalies are classified in 2 types: tumors and malformations.¹

Vascular tumors are distinguished by cellular proliferation and vascular malformations by dysplastic vessels, or aberrations in vascular genesis^{2, 3}. Both forms are under-classified in several types, taking into account clinical aspects, histopathology, physiopathology, evolution and prognosis. Diagnosing the exact type of anomaly is highly important, especially because of the therapy approach.

Vascular tumors appear solitary, such as in congenital or infantile hemangiomas, tufted hemangiomas, kaposiform hemangioendothelioma; or as part of associated malformations in several types of syndromes, such as Kassabach Meritt syndrome, PHACE syndrome and Lumbar syndrome (PELVIS, SACRAL syndrome).

Vascular malformations are under-classified after their flow characteristics³ in low-flow malformations, such as venous and lymphatic malformations, Sturge Weber syndrome or Klippel Trenaunay syndrome; and high-flow malformations, such as arteriovenous malformations. Most of them are present at birth, but there are situations in which they are only discovered after a few weeks.³ They tend to grow more rapidly with trauma, infection or hormonal changes⁴, becoming locally or systemically aggressive.⁴

Clinical aspects and diagnosis

1. VASCULAR TUMORS

Congenital hemangiomas

This type of hemangioma is present at birth⁵, but can be already found at 12 weeks of gestation.^{1,3,6} They grow in utero and at birth they have their final dimension.³ They can be seen in any area of the body, but have a head-neck predilection, and are frequently seen near joints.³ Depending on their postnatal involution they are under-classified in RICH (rapidly involuting

congenital hemangioma) and NICH (non-involuting congenital hemangioma).⁷

The RICH type is a violaceous tumor, usually devolves by 12-14 months^{1, 3, 6} often leaving a cutaneous and subcutaneous tissue defect. The NICH type does not follow the process of involution at all. Moreover, it tends to grow along with the child^{1, 3, 6}. Both can be diagnosed as fast-flow lesions by ultrasound or MRI¹, and, bioptically, they are both GLUT-1 negative tumors.⁶

Infantile hemangiomas

Infantile hemangiomas usually develop in the first few weeks after birth, and undergo three stages of evolution. The first one consists of endothelial cell proliferation and is known as the proliferative phase. The phase is followed by an involution phase, and afterwards by an involuted phase.⁷ They present themselves as tumors of variable sizes, forms and locations, ranging from 1 to 25 cm dimension⁸. Taking into account their dermal infiltration, they are classified in superficial, deep and mixed infantile hemangiomas⁹. The presence of GLUT-1 (glucose transporter 1) is pathognomonic for this type of anomaly, being present in each stage of evolution, and absent in all other types of vascular tumors or malformations.¹

In most situations infantile hemangiomas come as solitary tumors, but up to 30% have multiple lesions¹. The presence of multiple hemangiomas raises the question of other organs involvement, especially hepatic.¹

MRI is useful in the diagnosis and in appreciating adjacent tissue damage.¹⁰ CT has not proved its utility and angiography is more important in therapy than in diagnosis⁸. Moreover, biopsy puts the diagnosis of GLUT-1 positive tumor.⁵

Tufted hemangiomas. Kaposiform hemangioendothelioma. Kassabach Meritt syndrome

The most common types of hemangioma associated to the Kassabach Meritt syndrome are the kaposiform hemangioendothelioma (KHE) and the tufted angioma^{11, 1, 4}, but it can come as well with infantile hemangiomas.

The tufted hemangiomas are small round, erythematous lesions built of capillaries and pericytes into nodules or tufts¹, with the aspect of

“cannonballs”³. They affect mostly children under 5 years and are localized especially on the neck³, trunk and the extremities¹. Biologically, they are CD31 and CD34 immunopositive, and are thought to be a gentler form of KHE.³

The kaposiform hemangioendothelioma comes as a solitary tumor of the extremities, trunk or retroperitoneum in children under 1 year¹. They are red-purple masses, with infiltration into the subcutaneous tissue, with local aggression and risks of metastasis¹ and a high mortality rate.⁵ Histologically, they are, as well, CD31 and CD 34 immunopositive, and they appear as fascicles of spindled endothelial cells.³

Trombocytopenia, microangiopathic haemolytic anemia and consumptive coagulopathy associated to hemangiomas are the most important aspects of the Kassabach Meritt syndrome¹². Even if it's a rare disorder, affecting <1%¹² of infants with vascular tumors, its high-risk morbidity and mortality (30%¹²) underline the urgency of treatment. The localization of hemangiomas is extremely important, because their growth can lead to the compression of vital structures¹³ and this needs immediate attention. Histopathologically, the cause of the syndrome is the trapping of thrombocytes in the hemangioma, which raises the risk of bleeding, hemolytic anemia and DIC (disseminated intravascular coagulation). Clinically, the tumor becomes more firm and changes its color.³

Diagnosis is put on coagulation tests for the KM syndrome and imaging studies, such as MRI⁵, are required to study the tumors.

PHACE syndrome

The syndrome is an association of several malformations of the superior part of the body, with infantile hemangiomas. The acronym comes from **P**osterior fossa, **H**emangiomas of the head and neck, **A**rterial and **C**ardiovascular, **E**ye anomalies^{1, 14}. Incidence of cardiovascular anomalies, varies from 21% to 67% in several studies^{15, 16}, being both the most common extracutaneous disorder¹⁷ and the most potentially injurious. The coarctation of the aorta in PHACE syndrome is different from the ordinary congenital one, being characterized by multiple narrowing segments of the transverse aortic arch without left-heart involvement¹⁸. Vessel anomalies consist




Fig. 1. Classification of vascular anomalies

of dysplastic arteries, and the cerebral involvement is emphasized by dysplastic, narrowed or primitive embryonic carotid-vertebrobasilar connections of the cerebral arteries.¹⁸ Internal carotid artery stenosis has the highest risk for stroke.¹⁷ The eye matter is either primary, or secondary to the cerebro-vascular disorders¹⁷.

The lesions have an up to 18 months¹ proliferative phase and do not devolve completely. Complications are frequent, cutaneous ones imply scarring and ulceration¹ and systemic ones imply seizures, stroke or developmental delay¹ in up to 50% of affected patients.

The diagnosis is multidisciplinary and is based on MRI, an ophthalmologic, neurologic and cardiologic consult.^{1, 14}

Lumbar syndrome

The syndrome comprises hemangiomas in the lower part of the body with anomalies of other organs of the area. It is, as well, underclassified in the PELVIC syndrome and the SACRAL syndrome. The PELVIC syndrome is characterized by perineal hemangiomas with genital malformations, lipomyelomeningocele, vesicorenal anomalies or anal anomalies⁴. The SACRAL syndrome associates cutaneous, renal, urologic anomalies, spinal disrafism with lombosacral hemangioma.⁴ Rarely, it can be life-threatening, symptoms can vary from very subtle to severe ones.¹⁷ The diagnosis is based on multiple approaches, imaging for both hemangiomas and congenital anomalies.¹⁷

2. VASCULAR MALFORMATIONS

Capillary malformations

Capillary malformations are the most frequent vascular malformations in children and are composed of numerous dilated capillaries or venules^{19, 20}. They appear at birth and involute quickly, facial ones tend to become violaceous and trunk and limb stains tend to fade.³ They are maculas localized on different sites, mostly on the cephalic extremity.¹ Port-wine stains occur in 0,3% of infants, typically along the branches of the trigeminal nerve.³ Association to other malformations or vascular anomalies are assigned in reference to the capillary localization. Eyelid capillary malformations raise the question of concurrent ophthalmological involvement, e.g. Wyburn Mason syndrome. Trunk or extremity capillary involvement associated to venous or lymphatic malformations suggest a Klippel Trenaunay syndrome¹. Lumbar capillary malformations implicate possible CNS anomalies¹, and association to congenital CNS malformations raises the question of Sturge Weber syndrome.³

Diagnosis comprises clinical evaluation; Doppler ultrasound²⁰ and MRI/CT scan for the evaluation of associated congenital anomalies.¹

Sturge-Weber syndrome

The diagnosis of Sturge Weber syndrome is based on three important criteria: 1. Capillary malformations²¹, most often a port-wine stain present at birth, seen commonly in the distribution of the ophthalmic branch of the trigeminal nerve^{22, 1}. 2. A high-intraocular pressure (glaucoma) ipsilaterally^{21, 22}. 3. An ipsilateral leptomeningeal angiomatose²² with contralateral focal seizures²¹.

These 3 aspects explain the symptoms of the disorder. Cutaneous involvement is, as mentioned, characterized by port-wine stains with flat or elevated border, uni- or bilaterally, in the area of the trigeminal nerve²². Some studies suggest that the port-wine stains follow rather the embryonic vasculature of the face, than the trigeminal nerve branches.²¹ Glaucoma occurs in up to 60%^{22, 23} of affected patients, and underlines the importance of multidisciplinary approach. Retinal detachment and choroidal hemorrhage are possible complications of ocular involvement.²¹ CNS symptoms are the most upsetting

ones, with contralateral seizures (83%²²), headaches^{1, 22} developmental delay¹, hemiparesis¹ and learning and attention deficit.²² Seizures are thought to be a consequence of the chronic hypoxemia and decreased perfusion of the cortex²¹, and are the most frequent neurologic complication.²³ At birth children appear to be normal, with physiological development in the first months. Symptoms appear later, and are more or less severe depending on the case.^{1, 22}

Diagnosis is based on imaging, MRI being of better reliance.^{1, 22} Brain atrophy can only be seen after 2-3 years of life²². Moreover, calcification of the brain, absence of superficial cortical veins, dilatation of deep veins and choroid plexus malformations can, as well, be noted in this syndrome.²¹

Venous malformations(VM):

Superficial or deep lesions present at birth, represented by bluish, localized or diffuse veins are known as venous malformations.¹ They can be sporadic or intra-familial, with an autosomal –dominant pattern^{3, 20}. Superficial lesions are at risk for thrombosis¹, phlebolits are often^{5, 20} and cause pain and successively functional impotence. Deep lesions are at risk for affecting proximal structures, such as bones or muscles.^{1, 24} Coagulopathy is a disorder, that appears especially with large VM^{20, 24} and occurs as a result of venous stasis and vein anomalies.¹ Multiple injuries question possible syndromatic disorders, such as Maffucci syndrome or blue rubber bleb nevus syndrome.^{3, 25}

Clinical examination, plane radiographs, ultrasound or MRI evaluate the lesion²⁴. Blood tests, including coagulation are important to determine risk factors for clotting complications.¹

Lymphatic malformations

Lymphatic malformations are slow-flow lesions that appear either solitary or in association with other anomalies in a variety of syndromes. The predominant localizations imply the neck, head and the axillae^{3, 20}. Cystic lymphatic lesions come as macro- , microcystic or as mixed forms.^{26, 27} Mixed forms are the most frequent and comprise lesions of the other two types. Macrocystic lesions are characterized as lymphatic anomalies of more than 2 cm, with or without compression of adjacent structures.

Microcystic lesions are small vesicles with infiltration into fatty tissue or muscles.¹

Some of the lesions can be diagnosed prenatally, but most of them are visible after 2 years of age.²⁸ Ultrasound can put the diagnosis, but cannot determine their infiltration into adjacent tissues. MRI is the gold-standard for the diagnosis and for the diagnosis of the local extension.^{1, 20, 26, 29}

The rupture of these malformations can lead to bacterial superinfection, situation that imposes antibiotic therapy.¹

Klippel-Trenaunay syndrome

The syndrome is characterized by the classic triad: 1. Port-wine stains 2. Bone hypertrophy or soft tissue hypertrophy 3. Venous malformations (varicosities)^{23, 30, 31}

The capillary malformations are limited by the midline of the body³⁰, most often on the same side with the affected limb. They do not disappear, but can involute with time.³⁰ The bone or soft tissue hypertrophy can affect one or more sites, enlarging the limb or increasing its length^{23, 32}. Yet, 80-85% of patients have only one affected limb.³¹ Other deformities are, as well possible, such as macro- or syndactyly, dislocation of hip joint or split hand deformity.^{30, 31} Varicosities occur most often on the lateral side of the limb^{30, 32}, the vein of Servelle has been noted in 68-80%³¹ of cases. Lymphatic malformations can, as well, be associated.^{30, 31}

The diagnosis is mostly clinical, but imaging helps characterizing the exact form. X-rays, venography, CT and MRI are useful in describing the exact features of each case.^{31, 32}

Arterio-venous malformations

This rare³³ malformations are fast-flow lesions, warm, with a palpable thrill and an audible bruit¹ that can appear in every part of the body, but are mostly seen in head-neck region³³ or the trunk¹. They are arterial-venous communications without normal capillary beds^{3, 20, 24}, with an incidence of 40-60% present at birth³. They grow more rapidly in puberty, pregnancy, traumatic situations^{5, 27} or when surgery is incorrectly applied.¹ Their growth is based on the enlargement of already malformed vessels, and not on cellular proliferation³³. Histologically, there are capillaries, thick veins,

large arteries and arterioles with random distribution in a fibrous dermis.³

Depending on their clinical severity they are classified in 4 stages: 1. Quiescent maculas; 2. High-flow state with palpable thrill and throbbing; 3. Necrosis, ulceration or hemorrhage (even bone deformities); 4. Cardiac decompensation.^{3, 7}

CT, MRI³³ and MRA are useful for diagnosis of the lesion and its extension, helping therapy approach.¹ Angiography can be used as a diagnostic tool in this kind of malformations.²⁷

Treatment

The most important aspect of the therapy of vascular anomalies is whether treatment is necessary or not. In both situations, either tumors or malformations, benignity is more often than malignancy. Localization and subsequent complications are considerable elements to be taken into account in the decision of treating. Each type of tumor or malformation, with its individualized characteristics, has its own therapy indications, but there are specific group-targeted treatment regimens.

Treatment for vascular tumors

Corticotherapy has been a first-line treatment for a long time, using mostly Prednisolone in doses ranging from 2 to 5 mg/kg/day, for 4-8 weeks.³⁴ If after 4 weeks a hemangioma doesn't improve under steroids, it is considered corticoreistant.³⁴ Topical steroids, such as Bethamethasone are an option too, and nonetheless they avoid systemic steroids side effects.

Since 2008, Propranolol has been used in all types of hemangioma with good responses and few side effects.^{1, 35, 36} Doses range from 0,5 up to 2 mg/kg/day¹⁰. Topical beta-blockers are also an option; moreover they raise the compliance and avoid systemic adverse reactions.³⁷

Vincristine, an antineoplastic agent, with antiangiogenic effects³⁴ is used in corticoreistant and beta-blocker resistant hemangiomas, or in case of contraindications for other treatment options.¹

Lasertherapy is a useful method for small, superficial vascular tumors or for residual teleangiectasis after involution of hemangiomas.^{1, 25, 37} Embolization can be used in

hepatic hemangiomas, but need special attention due to its risks, like hepatic rupture or heart-failure.³⁸

Surgery is indicated in situations where tumors cause dysfunction, cosmetic impairment or when they are medication-resistant.³⁹

Treatment for vascular malformations

- Treatment for low-flow vascular malformations

In most situations sclerotherapy is the first option, and is used predominantly in venous⁴⁰ and macrocystic lymphatic malformations, complicated with recurrent swelling or phlebolits, functional impairment, deformity or infection.^{26, 40} Sclerosant options are based on etiology, venous malformations are mostly treated with ethanol²⁰, while lymphatic ones with Doxycycline²⁸. Complications of sclerotherapy are caused frequently by the extravasation of sclerosant; ulceration, blistering are seen often, while nerve injury and compartment syndrome are less frequent^{24, 26, 40}. Hemoglobinuria comes with large VM, and is transitory^{24, 26}. Laser photocoagulation, resection or multiple-therapy approaches are other choices of treatment.²⁴

Surgery is a second option in treating low-flow malformations, and it is used in cases where endovascular therapy, like sclerotherapy, has no results.³⁹

- Treatment for high-flow vascular malformations

Embolization is the first option for treating such malformative disorders and is individualized depending on the localization of the malformation.³³ It is applied either transarterially or transvenously²⁴ with several types of sclerosants³³.

Surgery is another choice³⁹ and is indicated in 2 main situations, one in which lesions are resectable and another one in which embolization has no chance of curing.³³ Combination of these two therapies is used successfully in more complicated types of AVM^{33, 39}.

Monoclonal antibodies, such as Bevacizumab, have been studied as AVM therapy and were shown to be efficient.³⁵ Important side effects are thrombembolic events, parasthesias and bleeding.³⁵

Conclusions

To conclude, the differential diagnosis of vascular anomalies is extremely important for the medical approach. Complications, prognosis and treatment differ in each situation, and it is essential to handle the cases based on their specific features.

Bibliografie/Bibliography

1. Azizkhan RG. Complex vascular anomalies. *Pediatr Surg Int.* 2013;29(10):1023-38.
2. Guevara CJ, Alomari AI. Interdisciplinary approach to treatment of vascular anomalies. *Tech Vasc Interv Radiol.* 2013;16(1):55-8.
3. Aboutaleb A, Jessup CJ, North PE, Mihm MC. Histopathology of vascular anomalies. *Facial Plast Surg.* 2012;28(6):545-53.
4. Blei F. Medical and genetic aspects of vascular anomalies. *Tech Vasc Interv Radiol.* 2013;16(1):2-11.
5. Tekes A, Koshy J, Kalayci TO, Puttgen K, Cohen B, Redett R, et al. S.E. Mitchell Vascular Anomalies Flow Chart (SEMVAFC): a visual pathway combining clinical and imaging findings for classification of soft-tissue vascular anomalies. *Clin Radiol.* 2014;69(5):443-57.
6. Hoeger PH, Colmenero I. Vascular tumours in infants. Part I: benign vascular tumours other than infantile haemangioma. *Br J Dermatol.* 2014;171(3):466-73.
7. Philandrianos C, Degardin N, Casanova D, Petit P, Bartoli JM, Bardot J, et al. [Diagnosis and management of vascular anomalies]. *Ann Chir Plast Esthet.* 2011;56(3):241-53.
8. Lucky AW. Lesiones cutaneas benignas transitorias en el recién nacido. In: Eichenfield LF, Frieden IJ, Esterly NB (eds). *Dermatologia neonatal.* 2ed. Spain. Elsevier. 2009:85-97
9. Talaat AA, Elbasiouny MS, Elgendy DS, Elwakil TF. Propranolol treatment of infantile hemangioma: clinical and radiologic evaluations. *J Pediatr Surg.* 2012;47(4):707-14.

10. Callahan AB, Yoon MK. Infantile hemangiomas: A review. *Saudi J Ophthalmol.* 2012;26(3):283-91.
11. Weston WL, Lane AT, Morelli JG. Lesiones vasculares. In: WestonWL, Lane AT, Morelli JG (eds). *Dermatologia pediátrica*. 4ed. Spain. Elsevier.2008:237-55
12. Ryan C, Price V, John P, Mahant S, Baruchel S, Brandao L, et al. Kasabach-Merritt phenomenon: a single centre experience. *Eur J Haematol.* 2010;84(2):97-104.
13. Champion RH, Burton JL, Burns DA, Breathnach SM. *Rook's Textbook of Dermatology*. 6th ed. Oxford Blackwell Science. 1998.
14. Bellaud G, Puzenat E, Billon-Grand NC, Humbert P, Aubin F. PHACE syndrome, a series of six patients: clinical and morphological manifestations, propranolol efficacy, and safety. *Int J Dermatol.* 2014.
15. Metry D, Heyer G, Hess C, Garzon M, Haggstrom A, Frommelt P, et al. Consensus Statement on Diagnostic Criteria for PHACE Syndrome. *Pediatrics.* 2009;124(5):1447-56.
16. Metry DW, Dowd CF, Barkovich AJ, Frieden IJ. The many faces of PHACE syndrome. *J Pediatr.* 2001;139(1):117-23.
17. Lee KC, Bercovitch L. Update on infantile hemangiomas. *Semin Perinatol.* 2013;37(1):49-58.
18. Bayer ML, Frommelt PC, Blei F, Breur JM, Cordisco MR, Frieden IJ, et al. Congenital cardiac, aortic arch, and vascular bed anomalies in PHACE syndrome (from the International PHACE Syndrome Registry). *Am J Cardiol.* 2013;112(12):1948-52.
19. Larralde M, Abad ME, Luna PC, Hoffner MV. Capillary malformation-arteriovenous malformation: a clinical review of 45 patients. *Int J Dermatol.* 2014;53(4):458-61.
20. Garzon MC, Huang JT, Enjolras O, Frieden IJ. Vascular malformations: Part I. *J Am Acad Dermatol.* 2007;56(3):353-70; quiz 71-4.
21. Waelchli R, Aylett SE, Robinson K, Chong WK, Martinez AE, Kinsler VA. New vascular classification of port-wine stains: improving prediction of Sturge-Weber risk. *Br J Dermatol.* 2014;171(4):861-7.
22. Reith W, Yilmaz U, Zimmer A. [Sturge-Weber syndrome]. *Radiologe.* 2013;53(12):1099-103.
23. Garzon MC, Huang JT, Enjolras O, Frieden IJ. Vascular malformations. Part II: associated syndromes. *J Am Acad Dermatol.* 2007;56(4):541-64.
24. Alomari A, Dubois J. Interventional management of vascular malformations. *Tech Vasc Interv Radiol.* 2011;14(1):22-31.
25. Brauer JA, Geronemus RG. Laser treatment in the management of infantile hemangiomas and capillary vascular malformations. *Tech Vasc Interv Radiol.* 2013;16(1):51-4.
26. Burrows PE. Endovascular treatment of slow-flow vascular malformations. *Tech Vasc Interv Radiol.* 2013;16(1):12-21.
27. Ernemann U, Kramer U, Miller S, Bisdas S, Rebmann H, Breuninger H, et al. Current concepts in the classification, diagnosis and treatment of vascular anomalies. *Eur J Radiol.* 2010;75(1):2-11.
28. Elluru RG, Balakrishnan K, Padua HM. Lymphatic malformations: diagnosis and management. *Semin Pediatr Surg.* 2014;23(4):178-85.
29. Blei F. Congenital lymphatic malformations. *Ann N Y Acad Sci.* 2008;1131:185-94.
30. Meier S. Klippel-Trenaunay syndrome: a case study. *Adv Neonatal Care.* 2009;9(3):120-4.
31. Zea MI, Hanif M, Habib M, Ansari A. Klippel-Trenaunay Syndrome: a case report with brief review of literature. *J Dermatol Case Rep.* 2009;3(4):56-9.
32. Kihiczak GG, Meine JG, Schwartz RA, Janniger CK. Klippel-Trenaunay syndrome: a multisystem disorder possibly resulting from a pathogenic gene for vascular and tissue overgrowth. *Int J Dermatol.* 2006;45(8):883-90.
33. Rosen RJ, Nassiri N, Drury JE. Interventional management of high-flow vascular malformations. *Tech Vasc Interv Radiol.* 2013;16(1):22-38.
34. Leaute-Labreze C, Sans-Martin V. [Infantile hemangioma]. *Presse Med.* 2010;39(4):499-510.
35. Blatt J, McLean TW, Castellino SM, Burkhart CN. A review of contemporary options for medical management of hemangiomas, other vascular tumors, and vascular malformations. *Pharmacol Ther.* 2013;139(3):327-33.
36. Saint-Jean M, Leaute-Labreze C, Mazereeuw-Hautier J, Bodak N, Hamel-Teillac D, Kupfer-Bessaguet I, et al. Propranolol for treatment of ulcerated infantile hemangiomas. *J Am Acad Dermatol.* 2011;64(5):827-32.
37. Behr GG, Johnson C. Vascular anomalies: hemangiomas and beyond—part 1, Fast-flow lesions. *AJR Am J Roentgenol.* 2013;200(2):414-22.
38. Rasalkar DD, Chu WC, Cheng FW, Lee V, Lee KH, Li CK. An institutional review of paediatric haemangiomas: prevalence, imaging features, and outcomes. *Hong Kong Med J.* 2010;16(5):334-40.

39. Waner M, O TM. The role of surgery in the management of congenital vascular anomalies. Tech Vasc Interv Radiol. 2013;16(1):45-50.
40. Odeyinde SO, Kangesu L, Badran M. Sclerotherapy for vascular malformations: complications and a review of techniques to avoid them. J Plast Reconstr Aesthet Surg. 2013;66(2):215-23.

Conflict de interese
NEDECLARATE

Conflict of interest
NONE DECLARED

Adresa de corespondență: Mădălina Bota
AMR
Str. Ionel Perlea nr 10
București

Correspondance address: Mădălina Bota
AMR
Str. Ionel Perlea no 10
Bucharest